Xiao Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiao Zheng has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Haiping Hao
College of Pharmacy, China Pharmaceutical University
24 shared publications Yuanlong Hou
13 shared publicationsXiaoying Cai
State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; Laboratory of Metabolic Regulation and Drug Target Discovery, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
12 shared publicationsYouying Zhang
12 shared publications- Xueli Zhang
Department of Pharmacy Zhongda Hospital Southeast University Nanjing China
10 shared publications Guangji Wang
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China
8 shared publications
Latest Publications
- 17 November 2026
- Published by Elsevier in Cell Metabolism
Diet-microbiome interaction shapes stress susceptibility via a gut-brain neurometabolic circuit
- 17 November 2026
- Published by Elsevier in Cell Metabolism
Diet-microbiome interaction shapes stress susceptibility via a gut-brain neurometabolic circuit
- 4 June 2026
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 47 (7) , 772-786
GPR35 in host–microbe interaction: Mechanisms and translational prospects
- 4 June 2026
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 47 (7) , 772-786
GPR35 in host–microbe interaction: Mechanisms and translational prospects
- 26 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (10) , e71966
Ketogenic Diet Modulates Depressive‐Like Behavior via Gut Bacterial Metabolism of Tyrosine
Emerging evidence suggests the therapeutic potential of ketogenic diet (KD) for mood disorders such as depression, yet the underlying mechanisms are poorly understood. Here we report a gut microbe‐to‐brain signaling pathway through which KD protects against depressive‐like behavior in mice. We show that KD feeding triggers a prompt and dynamic remodeling of the gut microbiome, the depletion of which abrogates the protective effect of KD against depressive‐like behavior in stressed mice. Colonization with Roseburia intestinalis ( R. intestinalis ), which is enriched by 1‐week KD, sustains the protective effect of KD against depressive‐like behavior in mice. The protective effect of KD is linked to the reduction of a host‐microbe co‐metabolite p‐Cresol sulfate (p‐CS), the supplementation of which negates the protective effect of KD against depressive‐like behavior. Mechanistically, p‐CS enters the brain and activates lateral habenula (LHb) to counteract the protective effect of KD. Our findings uncover a gut microbiota‐brain axis mechanism for KD consumption to protect against depressive‐like behavior.
- 26 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (10) , e71966
Ketogenic Diet Modulates Depressive‐Like Behavior via Gut Bacterial Metabolism of Tyrosine
Emerging evidence suggests the therapeutic potential of ketogenic diet (KD) for mood disorders such as depression, yet the underlying mechanisms are poorly understood. Here we report a gut microbe‐to‐brain signaling pathway through which KD protects against depressive‐like behavior in mice. We show that KD feeding triggers a prompt and dynamic remodeling of the gut microbiome, the depletion of which abrogates the protective effect of KD against depressive‐like behavior in stressed mice. Colonization with Roseburia intestinalis ( R. intestinalis ), which is enriched by 1‐week KD, sustains the protective effect of KD against depressive‐like behavior in mice. The protective effect of KD is linked to the reduction of a host‐microbe co‐metabolite p‐Cresol sulfate (p‐CS), the supplementation of which negates the protective effect of KD against depressive‐like behavior. Mechanistically, p‐CS enters the brain and activates lateral habenula (LHb) to counteract the protective effect of KD. Our findings uncover a gut microbiota‐brain axis mechanism for KD consumption to protect against depressive‐like behavior.
- Open Access
- 4 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding
While the impact of non-antibiotic drugs on gut bacteria is well-known, their mechanisms of action remain poorly characterized, and effective mitigation strategies for drug-induced dysbiosis are still limited. Here, we screened bacteria-derived drug-target protein homologs (BDTPHs) mapped to 63 target proteins and 107 associated drugs to quantify “drug–BDTPH–bacterium” interactions. These interactions were validated by co-culture experiments using 10 drugs and 25 strains, enzyme assays, and genetic perturbations in Escherichia coli. Ex vivo and in vivo testing with six drugs showed that over 50% of affected genera exhibited high affinity, indicating microbiota alterations through the “drug–BDTPH–bacterium” axis. Leveraging this quantitative interaction framework, we identified a strain of Bifidobacterium animalis that can competitively bind methotrexate through high-affinity BDTPH, thereby effectively alleviating gut microbiota dysbiosis in vivo. Our findings elucidate a mechanism by which non-antibiotic drug effects on bacterial growth, and suggest a universal homology-based competition strategy to restore drug-disrupted microbiota.
- 4 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessProbiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding
While the impact of non-antibiotic drugs on gut bacteria is well-known, their mechanisms of action remain poorly characterized, and effective mitigation strategies for drug-induced dysbiosis are still limited. Here, we screened bacteria-derived drug-target protein homologs (BDTPHs) mapped to 63 target proteins and 107 associated drugs to quantify “drug–BDTPH–bacterium” interactions. These interactions were validated by co-culture experiments using 10 drugs and 25 strains, enzyme assays, and genetic perturbations in Escherichia coli. Ex vivo and in vivo testing with six drugs showed that over 50% of affected genera exhibited high affinity, indicating microbiota alterations through the “drug–BDTPH–bacterium” axis. Leveraging this quantitative interaction framework, we identified a strain of Bifidobacterium animalis that can competitively bind methotrexate through high-affinity BDTPH, thereby effectively alleviating gut microbiota dysbiosis in vivo. Our findings elucidate a mechanism by which non-antibiotic drug effects on bacterial growth, and suggest a universal homology-based competition strategy to restore drug-disrupted microbiota.
- 2 March 2026
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 24 (3) , 349-364
Predicting cerebral acetylcholine dynamics with huperzine A pharmacokinetics in blood via mPBPK-PD modeling
- 2 March 2026
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 24 (3) , 349-364
Predicting cerebral acetylcholine dynamics with huperzine A pharmacokinetics in blood via mPBPK-PD modeling
- Open Access
- 1 January 2026
- Published by Maximum Academic Press in Targetome
- Vol. 2 (5)
Dual cognition-improving mechanisms of huperzine A in vascular dementia mice via neurometabolic regulation
Vascular dementia (VaD) is a poorly treated disease that involves complicated pathology such as neuronal damage and neural circuit dysfunction. Huperzine A (HupA) is commonly used for clinical treatment of cognitive impairment, the mechanism of which is prevalently attributed to the increase in synaptic acetylcholine (ACh) levels. Here we elucidate an integral neurometabolic mechanism for HupA in the treatment of cognitive impairment in VaD. HupA effectively alleviated bilateral common carotid artery occlusion (BCCAO)-induced neuronal damage, neuroinflammation, and cognitive decline in mice, accompanied by a notable restoration of ACh homeostasis in the dorsal striatum (STRd). HupA or ACh injection into the STRd recapitulated the cognitive effects, while an α7nAChR antagonist blocked the neuroprotective effects in both primary neurons and VaD mice. By neural circuit mapping and functional manipulation, we further identified that HupA-induced ACh accumulation in the STRd recruits a STRdGABA→SNrGABA neural circuit to synergistically improve the cognitive network in VaD mice. Overall, we reveal a dual mechanism orchestrated by STRd ACh signaling through which HupA confers cognitive improvement in VaD mice. These findings underscore the therapeutic value of targeting neurometabolic nodes for the treatment of VaD and potentially other forms of dementia.
- 1 January 2026
- Published by Maximum Academic Press in Targetome
- Vol. 2 (5)
Open AccessDual cognition-improving mechanisms of huperzine A in vascular dementia mice via neurometabolic regulation
Vascular dementia (VaD) is a poorly treated disease that involves complicated pathology such as neuronal damage and neural circuit dysfunction. Huperzine A (HupA) is commonly used for clinical treatment of cognitive impairment, the mechanism of which is prevalently attributed to the increase in synaptic acetylcholine (ACh) levels. Here we elucidate an integral neurometabolic mechanism for HupA in the treatment of cognitive impairment in VaD. HupA effectively alleviated bilateral common carotid artery occlusion (BCCAO)-induced neuronal damage, neuroinflammation, and cognitive decline in mice, accompanied by a notable restoration of ACh homeostasis in the dorsal striatum (STRd). HupA or ACh injection into the STRd recapitulated the cognitive effects, while an α7nAChR antagonist blocked the neuroprotective effects in both primary neurons and VaD mice. By neural circuit mapping and functional manipulation, we further identified that HupA-induced ACh accumulation in the STRd recruits a STRdGABA→SNrGABA neural circuit to synergistically improve the cognitive network in VaD mice. Overall, we reveal a dual mechanism orchestrated by STRd ACh signaling through which HupA confers cognitive improvement in VaD mice. These findings underscore the therapeutic value of targeting neurometabolic nodes for the treatment of VaD and potentially other forms of dementia.
- Open Access
- 23 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e08693
Taurocholic Acid Is Associated With Disturbed Functional Connectivity in the Hippocampus of Patients With Depression
Major Depressive Disorder (MDD) is characterized by abnormal metabolic profiles along the microbiome‐gut‐brain axis. Bile acids (BAs), a class of steroid compounds regulated by the host and microbes, are increasingly shown to become dysregulated in models of depression. However, the identity of key regulatory BA metabolite in patients with MDD and associated mechanism remain to be clarified. Here, a prospective observational study in patients with depression ( n = 235) and control subjects ( n = 232) for identifying functional BA metabolites regulating depressive behavior and brain functional connectivity is performed. Using comparative metabolomics assay, an increased level of taurocholic acid (TCA) in the serum of patients with MDD is observed, which is reversed by anti‐depressant treatments. Transferring fecal microbiome from patients with MDD induced TCA accumulation to the hippocampus of recipient mice exhibiting depression‐like behavior. TCA supplementation suppressed hippocampal neurogenesis, triggered microglial activation, and elicited depression‐like behavior in mice, which are alleviated by a sphingosine‐1‐phosphate receptor 2 (S1PR2) antagonist. In patients with MDD, functional neuroimaging and spearman correlation analysis revealed that circulating TCA is strongly correlated with functional connectivity in the subregions of hippocampus. The results highlight the potential of harnessing TCA as a prognostic marker and therapeutic target for depression.
- 23 December 2025
- Published by Wiley in Advanced Science
- Vol. 13 (13) , e08693
Open AccessTaurocholic Acid Is Associated With Disturbed Functional Connectivity in the Hippocampus of Patients With Depression
Major Depressive Disorder (MDD) is characterized by abnormal metabolic profiles along the microbiome‐gut‐brain axis. Bile acids (BAs), a class of steroid compounds regulated by the host and microbes, are increasingly shown to become dysregulated in models of depression. However, the identity of key regulatory BA metabolite in patients with MDD and associated mechanism remain to be clarified. Here, a prospective observational study in patients with depression ( n = 235) and control subjects ( n = 232) for identifying functional BA metabolites regulating depressive behavior and brain functional connectivity is performed. Using comparative metabolomics assay, an increased level of taurocholic acid (TCA) in the serum of patients with MDD is observed, which is reversed by anti‐depressant treatments. Transferring fecal microbiome from patients with MDD induced TCA accumulation to the hippocampus of recipient mice exhibiting depression‐like behavior. TCA supplementation suppressed hippocampal neurogenesis, triggered microglial activation, and elicited depression‐like behavior in mice, which are alleviated by a sphingosine‐1‐phosphate receptor 2 (S1PR2) antagonist. In patients with MDD, functional neuroimaging and spearman correlation analysis revealed that circulating TCA is strongly correlated with functional connectivity in the subregions of hippocampus. The results highlight the potential of harnessing TCA as a prognostic marker and therapeutic target for depression.
- 20 November 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (6) , 547-563
Tryptophan metabolites at the service of neuroimmune sensing of microbes
- 20 November 2025
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (6) , 547-563
Tryptophan metabolites at the service of neuroimmune sensing of microbes
Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites
Background: Late-onset diarrhoea remains a poorly managed concern for clinical irinotecan therapy. Although bacterial β-glucuronidases (β-GUS) mediated SN-38 production is prevailingly thought to mediate intestinal toxicity, β-GUS inhibitors confer limited benefits in the clinic. Objective: This study aimed to explore the role and mechanism of endogenous bacterial metabolites in susceptibility to irinotecan toxicity. Design: Gut microbiota profiles and metabolites in patients with colorectal cancer (CRC) with or without diarrhoea were investigated via 16S rRNA sequencing, shotgun metagenomics and metabolomics. The role of microbial metabolites was investigated in mice by metabolic bioengineering and intestinal organoid culture. The mechanism of microbial metabolites on intestinal stem cells was investigated by transcriptional profiling and chemical intervention. Results: Gut microbial configuration was differentially remodelled in diarrhoea and non-diarrhoea patients with irinotecan therapy, and the susceptibility was transmissible to recipient mice via transplantation of baseline faecal microbiome. Bacteroides intestinalis ( B. intestinalis ) was notably expanded in the diarrhoea-prone cohorts as well as in irinotecan-treated mice. B. intestinalis colonisation sensitised intestinal epithelia to irinotecan-induced chemical injury, partially via tryptophan metabolite indole-3-acetate (IAA). Both B. intestinalis and bioengineered bacteria that produce IAA exacerbated irinotecan-induced intestinal epithelial injury in mice. Mechanistically, IAA suppressed PI3K-Akt signalling, thereby impairing the renewal of intestinal epithelia under the insult of irinotecan. In clinical patients receiving irinotecan therapy, faecal IAA level was closely associated with the diarrhoea severity. Conclusion: Our study uncovers the mechanism of endogenous bacterial metabolite in shaping the individual susceptibility to irinotecan toxicity and suggests IAA as a potential predictive biomarker.
Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites
Background: Late-onset diarrhoea remains a poorly managed concern for clinical irinotecan therapy. Although bacterial β-glucuronidases (β-GUS) mediated SN-38 production is prevailingly thought to mediate intestinal toxicity, β-GUS inhibitors confer limited benefits in the clinic. Objective: This study aimed to explore the role and mechanism of endogenous bacterial metabolites in susceptibility to irinotecan toxicity. Design: Gut microbiota profiles and metabolites in patients with colorectal cancer (CRC) with or without diarrhoea were investigated via 16S rRNA sequencing, shotgun metagenomics and metabolomics. The role of microbial metabolites was investigated in mice by metabolic bioengineering and intestinal organoid culture. The mechanism of microbial metabolites on intestinal stem cells was investigated by transcriptional profiling and chemical intervention. Results: Gut microbial configuration was differentially remodelled in diarrhoea and non-diarrhoea patients with irinotecan therapy, and the susceptibility was transmissible to recipient mice via transplantation of baseline faecal microbiome. Bacteroides intestinalis ( B. intestinalis ) was notably expanded in the diarrhoea-prone cohorts as well as in irinotecan-treated mice. B. intestinalis colonisation sensitised intestinal epithelia to irinotecan-induced chemical injury, partially via tryptophan metabolite indole-3-acetate (IAA). Both B. intestinalis and bioengineered bacteria that produce IAA exacerbated irinotecan-induced intestinal epithelial injury in mice. Mechanistically, IAA suppressed PI3K-Akt signalling, thereby impairing the renewal of intestinal epithelia under the insult of irinotecan. In clinical patients receiving irinotecan therapy, faecal IAA level was closely associated with the diarrhoea severity. Conclusion: Our study uncovers the mechanism of endogenous bacterial metabolite in shaping the individual susceptibility to irinotecan toxicity and suggests IAA as a potential predictive biomarker.
- 20 February 2025
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 23 (2) , 158-168
Metabolic insights into gut microbiota in the pharmacology of natural medicines
- 20 February 2025
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 23 (2) , 158-168
Metabolic insights into gut microbiota in the pharmacology of natural medicines